[go: up one dir, main page]

DK3710000T3 - Tradipitant til anvendelse til behandling af gastroparese - Google Patents

Tradipitant til anvendelse til behandling af gastroparese Download PDF

Info

Publication number
DK3710000T3
DK3710000T3 DK18821773.1T DK18821773T DK3710000T3 DK 3710000 T3 DK3710000 T3 DK 3710000T3 DK 18821773 T DK18821773 T DK 18821773T DK 3710000 T3 DK3710000 T3 DK 3710000T3
Authority
DK
Denmark
Prior art keywords
tradipitant
gastroparesis
treatment
Prior art date
Application number
DK18821773.1T
Other languages
English (en)
Inventor
Mihael H Polymeropoulos
Gunther Birznieks
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3710000T3 publication Critical patent/DK3710000T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK18821773.1T 2017-11-17 2018-11-16 Tradipitant til anvendelse til behandling af gastroparese DK3710000T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587681P 2017-11-17 2017-11-17
PCT/US2018/061593 WO2019099883A1 (en) 2017-11-17 2018-11-16 Method of treatment of gastrointestinal diseases with tradipitant

Publications (1)

Publication Number Publication Date
DK3710000T3 true DK3710000T3 (da) 2025-06-16

Family

ID=64734107

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18821773.1T DK3710000T3 (da) 2017-11-17 2018-11-16 Tradipitant til anvendelse til behandling af gastroparese

Country Status (19)

Country Link
US (4) US20200030307A1 (da)
EP (1) EP3710000B1 (da)
JP (1) JP7306614B2 (da)
KR (2) KR20250140655A (da)
CN (2) CN111343981A (da)
AU (1) AU2018367623B2 (da)
BR (1) BR112020009520A2 (da)
CA (1) CA3081582A1 (da)
CL (1) CL2020001290A1 (da)
DK (1) DK3710000T3 (da)
ES (1) ES3032138T3 (da)
FI (1) FI3710000T3 (da)
HR (1) HRP20250615T1 (da)
HU (1) HUE071527T2 (da)
IL (1) IL274541B2 (da)
MX (1) MX2020005167A (da)
PT (1) PT3710000T (da)
SI (1) SI3710000T1 (da)
WO (1) WO2019099883A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385788B (es) * 2015-03-04 2025-03-18 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant.
JP7410137B2 (ja) * 2018-06-08 2024-01-09 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントを用いる処置方法
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020069092A1 (en) * 2018-09-28 2020-04-02 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
EP3890735A1 (en) * 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
EP4125811A1 (en) 2020-03-26 2023-02-08 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
EP4637766A1 (en) 2022-12-21 2025-10-29 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1501809E (pt) 2002-04-26 2008-03-18 Lilly Co Eli Derivados de triazole como antagonistas de receptores de taquiquinina
EA008881B1 (ru) * 2003-10-24 2007-08-31 Эли Лилли Энд Компани Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
DK2121610T3 (da) 2006-12-20 2014-06-30 Lilly Co Eli Hidtil ukendt mellemprodukt og fremgangsmåde, som er anvendelige ved fremstilling af {2-[1-(3,5-bis-trifluormethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorphenyl)-methanon
PH12012500887A1 (en) * 2009-11-18 2016-08-26 Helsinn Healthcare Sa Compositions for treating centrally mediated nausea and vomiting
MX385788B (es) * 2015-03-04 2025-03-18 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant.
EP3393519A1 (en) * 2015-12-22 2018-10-31 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors

Also Published As

Publication number Publication date
JP2021503480A (ja) 2021-02-12
NZ764107A (en) 2024-07-05
CN119074729A (zh) 2024-12-06
US20230390269A1 (en) 2023-12-07
US20210330656A1 (en) 2021-10-28
IL274541B2 (en) 2024-10-01
EP3710000B1 (en) 2025-04-23
US20200030307A1 (en) 2020-01-30
ES3032138T3 (en) 2025-07-15
SI3710000T1 (sl) 2025-07-31
HRP20250615T1 (hr) 2025-07-18
KR20200088346A (ko) 2020-07-22
KR102864285B1 (ko) 2025-09-24
AU2018367623A1 (en) 2020-05-21
PT3710000T (pt) 2025-05-29
AU2018367623B2 (en) 2024-03-28
RU2020119259A (ru) 2021-12-17
BR112020009520A2 (pt) 2020-11-03
KR20250140655A (ko) 2025-09-25
CA3081582A1 (en) 2019-05-23
CN111343981A (zh) 2020-06-26
US20210093621A1 (en) 2021-04-01
IL274541B1 (en) 2024-06-01
EP3710000A1 (en) 2020-09-23
MX2020005167A (es) 2020-08-20
WO2019099883A1 (en) 2019-05-23
HUE071527T2 (hu) 2025-09-28
CL2020001290A1 (es) 2020-11-13
IL274541A (en) 2020-06-30
FI3710000T3 (fi) 2025-07-03
JP7306614B2 (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
PL3265053T3 (pl) Sposoby leczenia skóry
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3524255T3 (da) Sammensætning til behandling af acne
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3391902T5 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3532067T3 (da) Liposomal formulering til anvendelse til behandling af cancer
IL251904B (en) Apilimod for use in the treatment of melanoma